However, when chondrocytes were previously treated with MiodesinTM, they showed a significant reduction in the secretion of this chemokine, as well as mRNA levels, suggesting an important role of MiodesinTM in the modulation of this chemokine, which has a primary function of attracting lymphocytes and monocytes as well as other cell types [38, 39] and of activating rheumatoid arthritis synovial fibroblasts (RASFs) to promote MMP-1 and MMP-13 mediated ECM destruction [40]. This evidence concerns the gene MMP1 and rheumatoid arthritis.